79 related articles for article (PubMed ID: 10071595)
1. Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trial.
Tetef M; Leong L; Ahn C; Akman S; Chow W; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Doroshow JH
Cancer Invest; 1999; 17(2):114-7. PubMed ID: 10071595
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy with cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (CDDP) for squamous cancers of the upper aerodigestive tract.
Margolin K; Doroshow J; Leong L; Akman S; Carr BI; Odujinrin O; Flanagan B
Am J Clin Oncol; 1989 Dec; 12(6):494-7. PubMed ID: 2589230
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer.
Schilsky RL; Muscato JJ; Muscato MS; Perry MC
Cancer Treat Rep; 1984 Sep; 68(9):1097-102. PubMed ID: 6541094
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin plus cytosine arabinoside in adults with malignant gliomas.
Stewart DJ; Richard MT; Benoit B; Hugenholtz H; Russell N; Dennery J; Peterson E; Grahovac Z; Belanger G; Aitkens S
J Neurooncol; 1984; 2(1):29-34. PubMed ID: 6088723
[TBL] [Abstract][Full Text] [Related]
5. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Gu Y; Shu Y; Xu Q
Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of high-dose cytosine arabinoside and cisplatin in recurrent squamous carcinoma of the head and neck. A Piedmont Oncology Association Study.
Powell BL; Craig JB; Muss HB; Zekan PJ; Cooper MR; Schnell FM; Hampton JW; White DR; Smith LR; Capizzi RL
Am J Clin Oncol; 1988 Oct; 11(5):550-2. PubMed ID: 3177257
[TBL] [Abstract][Full Text] [Related]
7. Modulation of cisplatin antitumor activity by short infusional high-dose cytosine arabinoside in advanced pretreated head and neck carcinoma: a phase II study.
Jelic S; Mitrovic L; Kovcin V; Nikolic-Tomasevic Z; Radulovic S; Tomasevic Z; Popov I
J Chemother; 1996 Aug; 8(4):304-9. PubMed ID: 8873838
[TBL] [Abstract][Full Text] [Related]
8. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
[TBL] [Abstract][Full Text] [Related]
9. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
10. [Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II), cytosine arabinoside and 5-fluorouracil, for advanced urothelial cancer].
Yamauchi T; Hida S; Ooishi K; Okada K; Yoshida O
Hinyokika Kiyo; 1985 Jul; 31(7):1093-104. PubMed ID: 2414981
[TBL] [Abstract][Full Text] [Related]
11. [Cisplatin and cytosine arabinoside (ARA-C) for the therapy of primary and secondary pleural neoplasms].
Aitini E; Cavazzini G; Cantore M; Rabbi C; Smerieri F
G Ital Oncol; 1990; 10(3):85-8. PubMed ID: 2286397
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of high-dose cytarabine and cisplatin in patients with advanced malignancy.
Atkins JN; Muss HB; Capizzi RL; Cooper MR; Craig J; Cruz JM; Jackson DV; Powell B; Richards F; Spurr CL
Cancer Treat Rep; 1985; 69(7-8):897-9. PubMed ID: 4040427
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model.
Albain KS; Swinnen LJ; Erickson LC; Stiff PJ; Fisher RI
Cancer Chemother Pharmacol; 1990; 27(1):33-40. PubMed ID: 2245491
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy of cisplatin and 5-FU in advanced colorectal carcinoma.
Dy C; Gil A; Algarra SM; Aparicio LA; Calvo F; Herranz P
Cancer Treat Rep; 1986 Apr; 70(4):465-8. PubMed ID: 3698039
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
Budd GT; Metch B; Weiss SA; Weick JK; Fabian C; Stephens RL; Balcerzak SP
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S213-6. PubMed ID: 8453701
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
Osman I; Akin U; Ismet A; Meral B; Hamdi A; Haluk K
Haematologia (Budap); 1996; 27(2):93-7. PubMed ID: 14651226
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
[TBL] [Abstract][Full Text] [Related]
20. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
Tummarello D; Graziano F; Isidori P; Santo A; Cetto G; Fedeli A; Rossi G; Cellerino R
Cancer; 1996 Jun; 77(11):2251-7. PubMed ID: 8635092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
